Literature DB >> 27474781

Appraisal of inflammation-based prognostic scores in patients with unresectable perihilar cholangiocarcinoma.

Masataka Okuno1, Tomoki Ebata1, Yukihiro Yokoyama1, Tsuyoshi Igami1, Gen Sugawara1, Takashi Mizuno1, Junpei Yamaguchi1, Masato Nagino2.   

Abstract

BACKGROUND: Inflammation-based prognostic scores are useful prognostic indicators for several types of cancer. The aim of this study was to evaluate whether the scores predict survival impact in unresectable perihilar cholangiocarcinoma.
METHODS: The modified Glasgow Prognostic Score (mGPS), Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio, and Prognostic Nutritional Index, were retrospectively assessed in 219 patients with unresectable perihilar cholangiocarcinoma.
RESULTS: Of the four scores evaluated, mGPS and NLR demonstrated prognostic value, whereas the remaining two systems did not. The median survival time (MST) of patients with a mGPS of 0 and NLR of 0 or 1 were significantly better than that of patients with a mGPS of 1 or 2 and NLR of 2 (12.3 vs. 4.8 months, P < 0.001, and 10.5 vs. 4.4 months, P = 0.001). Multivariate analysis revealed that both mGPS and NLR were independent prognostic factors. The combination of mGPS and NLR stratified survival well: the MST was 12.8 months in patients with a mGPS of 0 and NLR of 1 or 2, while only 3.0 months in patients with a mGPS of 1 or 2 and NLR of 2.
CONCLUSIONS: Both mGPS and NLR are independent prognostic factors and pivotal in refining patient stratification in unresectable perihilar cholangiocarcinoma.
© 2016 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Glasgow prognostic score; Neutrophil lymphocyte ratio; Perihilar cholangiocarcinoma; Prognosis; Survival analysis

Mesh:

Year:  2016        PMID: 27474781     DOI: 10.1002/jhbp.386

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  7 in total

1.  The Prognostic Impact of the Lymphocyte-to-Monocyte Ratio in Resected Pancreatic Head Adenocarcinoma.

Authors:  Shunsuke Onoe; Atsuyuki Maeda; Yuichi Takayama; Yasuyuki Fukami; Takamasa Takahashi; Masahito Uji; Yuji Kaneoka
Journal:  Med Princ Pract       Date:  2019-05-20       Impact factor: 1.927

2.  Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells.

Authors:  Jiehong Zeng; Zhengkai Liu; Shuwen Sun; Jianhong Xie; Li Cao; Pin Lv; Shengdan Nie; Bao Zhang; Bowen Xie; Siyuan Peng; Bo Jiang
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

3.  Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma.

Authors:  Hai-Jie Hu; Yan-Wen Jin; Rong-Xing Zhou; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  J Gastrointest Surg       Date:  2018-08-03       Impact factor: 3.452

4.  Inflammation-based prognostic scores in patients with extrahepatic bile duct lesions treated by percutaneous transhepatic biliary stenting combined with 125I seeds intracavitary irradiation.

Authors:  X Hu; Q Pang; H Liu; Z Qian; H Jin; L Zhou; Y Wang; Z Man; Z Li; S Yang
Journal:  Clin Transl Oncol       Date:  2018-10-27       Impact factor: 3.405

5.  Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection.

Authors:  Yong Zhang; Shi-Ming Shi; Hua Yang; Liu-Xiao Yang; Zheng Wang; Xue-Dong Li; Dan Yin; Ying-Hong Shi; Ya Cao; Zhi Dai; Jian Zhou; Qing Chen
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

6.  The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Dong Liu; Lara R Heij; Zoltan Czigany; Edgar Dahl; Marcel den Dulk; Sven A Lang; Tom F Ulmer; Ulf P Neumann; Jan Bednarsch
Journal:  Sci Rep       Date:  2022-07-25       Impact factor: 4.996

7.  Outcome and validation of a new clinically based staging system for predicting survival of perihilar cholangiocarcinoma patients.

Authors:  Passisd Laoveeravat; Veeravich Jaruvongvanich; Nicha Wongjarupong; Sittikorn Linlawan; Natthaporn Tanpowpong; Chonlada Phathong; Parkpoom Phatharacharukul; Sombat Treeprasertsuk; Rungsun Rerknimitr; Roongruedee Chaiteerakij
Journal:  JGH Open       Date:  2017-10-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.